Next Article in Journal
A Chemiluminescent Method for the Detection of H2O2 and Glucose Based on Intrinsic Peroxidase-Like Activity of WS2 Quantum Dots
Previous Article in Journal
Optimization of the Extraction Process to Obtain a Colorant Ingredient from Leaves of Ocimum basilicum var. purpurascens
Previous Article in Special Issue
New Anti-inflammatory Flavonol Glycosides from Lindera akoensis Hayata
Article Menu
Issue 4 (February-2) cover image

Export Article

Open AccessArticle
Molecules 2019, 24(4), 687;

Inhibition of Amyloid Beta Aggregation and Deposition of Cistanche tubulosa Aqueous Extract

Sinphar Pharmaceutical Co., Ltd., Sinphar Group, Yilan 269, Taiwan
Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan
School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan
Sinphar Tian-Li Pharmaceutical Co., Ltd., Sinphar Group, Hangzhou 311100, China
Authors to whom correspondence should be addressed.
Received: 17 January 2019 / Revised: 13 February 2019 / Accepted: 13 February 2019 / Published: 14 February 2019
(This article belongs to the Special Issue The Potential Use of Herbal Medicinal Products in Chronic Disorders)
Full-Text   |   PDF [2859 KB, uploaded 14 February 2019]   |  
  |   Review Reports


Cistanche tubulosa aqueous extract (CTE) is already used as a botanical prescription drug for treating dementia in China. Our previous studies reported that phenylethanoid glycosides of CTE have anti-Alzheimer’s disease (AD) activity by inhibiting amyloid β peptide (Aβ) aggregation and deposition. However, recent studies considered that the phenylethanoid glycosides may be metabolized by intestinal bacteria, because all analysis results showed that the bioavailability of phenylethanoid glycosides is extremely low. In this study we demonstrate how iron chelation plays a crucial role in the Aβ aggregation and deposition inhibition mechanism of phenylethanoid glycosides of CTE. In addition, we further proved phenylethanoid glycosides (13) could reach brain. Active CTE component and action mechanism confirmation will be a great help for product quality control and bioavailability studies in the future. At the same time, we provide a new analysis method useful in determining phenylethanoid glycosides (13) in plants, foods, blood, and tissues for chemical fingerprint and pharmacokinetic research. View Full-Text
Keywords: Cistanche tubulosa; phenylethanoid glycosides; Alzheimer’s disease; iron chelation Cistanche tubulosa; phenylethanoid glycosides; Alzheimer’s disease; iron chelation

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Chao, C.-L.; Huang, H.-W.; Huang, H.-C.; Chao, H.-F.; Yu, S.-W.; Su, M.-H.; Wang, C.-J.; Lin, H.-C. Inhibition of Amyloid Beta Aggregation and Deposition of Cistanche tubulosa Aqueous Extract. Molecules 2019, 24, 687.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top